Introduction Oral therapies for moderate-to-severe plaque psoriasis remain limited, especially those offering biologic-level efficacy with favorable safety profiles (1). TYK2 inhibition has emerged as a targeted, selective approach that bypasses broader JAK-related adverse events. This case explores the clinical management of a middle-aged male pat